Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 7/20 | 0.45 |
| ▸ | CA2 | P00918 | 7/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4618539 | 0.85 | HSPA5 (0.48) | HSPA5CYP2D6TSHRHIF1ATAAR1 | |
| SCHEMBL8939979 | 0.82 | HSPA5 (0.50) | HSPA5CYP2D6TSHRHIF1ATAAR1 | |
| SCHEMBL4619740 | 0.81 | HSPA5 (0.45) | HSPA5CYP2D6TSHRHIF1ATAAR1 | |
| Formaldehyde SCHEMBL2787786 | 0.80 | HSPA5 (0.43) | HSPA5CYP2D6TSHRHIF1ATAAR1 | |
| SCHEMBL8931392 | 0.78 | HSPA5 (0.56) | HSPA5CYP2D6TSHRHIF1ATAAR1 | |
| SCHEMBL4618534 | 0.77 | TAAR1 (0.54) | HSPA5CYP2D6TSHRHIF1ATAAR1 | |
| SCHEMBL6368754 | 0.76 | HSPA5 (0.54) | HSPA5CYP2D6TSHRHIF1ATAAR1 | |
| SCHEMBL108067 | 0.76 | GABRA1 (0.64) | HSPA5CYP2D6TSHRHIF1ATAAR1 | |
| SCHEMBL11223294 | 0.76 | HSPA5 (0.54) | HSPA5CYP2D6TSHRHIF1ATAAR1 | |
| SCHEMBL3071437 | 0.76 | HSPA5 (0.54) | HSPA5CYP2D6TSHRHIF1ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180327671-A1 | FLAME RETARDANT LIQUID SOLUTION, POLYURETHANE FOAM-FORMING COMPOSITIONS, POLYURETHANE FOAM AND ARTICLES MADE THEREFROM | ICL-IP AMERICA INC. | 2018-11-15 | — | — | US | disclosed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2684874-A1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | Cephalon, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| EP-1893680-A1 | FLAME RETARDANT COMPOSITION EXHIBITING SUPERIOR THERMAL STABILITY AND FLAME RETARDING PROPERTIES AND USE THEREOF | ALBEMARLE CORPORATION (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070018143-A1 | Flame retardant composition exhibiting superior thermal stability and flame retarding properties and use thereof | ALBEMARLE CORPORATION | 2007-01-25 | — | — | US | disclosed |
| WO-2006132900-A1 | FLAME RETARDANT COMPOSITION EXHIBITING SUPERIOR THERMAL STABILITY AND FLAME RETARDING PROPERTIES AND USE THEREOF | ALBEMARLE CORPORATION (US) | 2006-12-14 | — | — | WO | disclosed |
| EP-1627013-A2 | STABILIZED FLAME RETARDANT ADDITIVES AND THEIR USE | ALBEMARLE CORPORATION (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1127917-B1 | Flame-retardant thermoplastic resin composition | AJINOMOTO KK (JP) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004104098-A2 | STABILIZED FLAME RETARDANT ADDITIVES AND THEIR USE | ALBEMARLE CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040229982-A1 | Stabilized flame retardant additives and their use | GOOSSENS DANIELLE F (BE) | 2004-11-18 | — | — | US | disclosed |
| US-6500889-B2 | BROMINATED FLAME RETARDANT, DOLOMITE AND ONE OF: HYDROTALCITE, ZINC-SUBSTITUTED HYDROTALCITE, OR ZEOLITE; HEAT STABILIZING | AJINOMOTO CO., INC. (JP) | 2002-12-31 | — | — | US | disclosed |
| US-20010044488-A1 | Flame-retarded thermoplastic resin composition | AJINOMOTO CO. INC. (JP) | 2001-11-22 | — | — | US | disclosed |
| EP-1127917-A1 | Flame-retardant thermoplastic resin composition | Ajinomoto Co., Inc. (JP) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | HSPA5 2819/4885CYP2D6 1017/4885TSHR 1728/4885 |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | HSPA5 2819/4885CYP2D6 1017/4885TSHR 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.